Literature DB >> 24917661

The influence of ART on the treatment of Trichomonas vaginalis among HIV-infected women.

Alys Adamski1, Rebecca A Clark2, Leandro Mena3, Harold Henderson3, Judy Levison4, Norine Schmidt1, Hirut T Gebrekristos1, David H Martin2, Patricia Kissinger1.   

Abstract

OBJECTIVE: Among women who are human immunodeficiency virus positive (HIV+), both prevalent and persistent infections with Trichomonas vaginalis (TV) are common. TV has been shown to increase vaginal shedding of HIV, which may influence HIV sexual and perinatal transmission, making prevention important. In 1 cohort of HIV+ women in Kenya, antiretroviral therapy (ART) use, mostly nevirapine based, was associated with lower cure rates of TV for single-dose therapy. Our goal was to repeat this study in a US-based cohort of HIV+/TV+ women and compare outcomes to those with multidose therapy.
METHODS: A secondary data analysis was performed on a multicentered cohort of HIV+/TV+ women who were randomized to single-dose (2 grams) or 7-day (500 mg twice daily) multidose metronidazole (MTZ) treatment. Test of cure visit, via culture, occurred 6-12 days after treatment completion. Information was collected on sex partner treatment and sexual exposures. Persistent TV infection rates were compared for women on ART at baseline vs not on ART.
RESULTS: Of the 226 women included, those on ART had more treatment failures than women not on ART (24/146 [16.4%] vs 5/80 [6.3%]; P = .03). When stratified by treatment arm, more treatment failures were seen in the single-dose arm (17/73 [23.3%] vs 3/39 [7.7%]; P = .05) than in the multidose arm (7/73 [9.6%] vs 2/41 [4.8%]; P = .39).
CONCLUSIONS: ART usage was associated with a higher TV persistent infection rate among those receiving the single-dose treatment, but not the multidose, providing more evidence that multidose should be the preferred treatment for HIV+ women.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; Trichomonas vaginalis; antiretroviral; metronidazole

Mesh:

Substances:

Year:  2014        PMID: 24917661      PMCID: PMC4200043          DOI: 10.1093/cid/ciu401

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic.

Authors:  G Schmid; E Narcisi; D Mosure; W E Secor; J Higgins; H Moreno
Journal:  J Reprod Med       Date:  2001-06       Impact factor: 0.142

2.  Interrelationships among human immunodeficiency virus type 1 infection, bacterial vaginosis, trichomoniasis, and the presence of yeasts.

Authors:  Prashini Moodley; Cathy Connolly; A Willem Sturm
Journal:  J Infect Dis       Date:  2001-12-04       Impact factor: 5.226

3.  Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women.

Authors:  L M Niccolai; J J Kopicko; A Kassie; H Petros; R A Clark; P Kissinger
Journal:  Sex Transm Dis       Date:  2000-05       Impact factor: 2.830

4.  Trichomonas vaginalis and amplification of HIV-1 transmission.

Authors:  F Sorvillo; P Kerndt
Journal:  Lancet       Date:  1998-01-17       Impact factor: 79.321

5.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

Review 6.  Trichomonas vaginalis, HIV, and African-Americans.

Authors:  F Sorvillo; L Smith; P Kerndt; L Ash
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

7.  A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women.

Authors:  Jennifer E Balkus; Barbra A Richardson; Vernon Mochache; Vrasha Chohan; Jeannie D Chan; Linnet Masese; Juma Shafi; Jeanne Marrazzo; Carey Farquhar; R Scott McClelland
Journal:  Sex Transm Dis       Date:  2013-06       Impact factor: 2.830

8.  Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity?

Authors:  Manya Magnus; Rebecca Clark; Leann Myers; Thomas Farley; Patricia J Kissinger
Journal:  Sex Transm Dis       Date:  2003-11       Impact factor: 2.830

9.  Correlates of incident Trichomonas vaginalis infections among African American female adolescents.

Authors:  Andrea Swartzendruber; Jessica M Sales; Jennifer L Brown; Ralph J Diclemente; Eve S Rose
Journal:  Sex Transm Dis       Date:  2014-04       Impact factor: 2.830

10.  Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010.

Authors:  Robert D Kirkcaldy; Peter Augostini; Lenore E Asbel; Kyle T Bernstein; Roxanne P Kerani; Christie J Mettenbrink; Preeti Pathela; Jane R Schwebke; W Evan Secor; Kimberly A Workowski; Darlene Davis; Jim Braxton; Hillard S Weinstock
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

View more
  5 in total

1.  Infectious disease: New Trichs: screening and therapy.

Authors:  David Killock
Journal:  Nat Rev Urol       Date:  2014-07-01       Impact factor: 14.432

2.  Epidemiology and treatment of trichomoniasis.

Authors:  Patricia Kissinger
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

3.  Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Patricia J Kissinger; Charlotte A Gaydos; Arlene C Seña; R Scott McClelland; David Soper; W Evan Secor; Davey Legendre; Kimberly A Workowski; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 20.999

Review 4.  Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues.

Authors:  Patricia Kissinger
Journal:  BMC Infect Dis       Date:  2015-08-05       Impact factor: 3.090

5.  Persistent Chlamydia trachomatis, Neisseria gonorrhoeae or Trichomonas vaginalis positivity after treatment among human immunodeficiency virus-infected pregnant women, South Africa.

Authors:  Andrew Medina-Marino; Maanda Mudau; Noah Kojima; Remco Ph Peters; Ute D Feucht; Lindsey De Vos; Dawie Olivier; Christina A Muzny; James A McIntyre; Jeffrey D Klausner
Journal:  Int J STD AIDS       Date:  2020-02-23       Impact factor: 1.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.